{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T02:06:27Z","timestamp":1784167587119,"version":"3.55.0"},"reference-count":25,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by proliferation of the granulocytic cell line. The incidence of CML in Kenya is estimated at near 2000 cases annually. The disorder is associated with a poor prognosis without treatment. Tyrosine kinase inhibitors are approved for treatment in adults and children with confirmed disease. Diagnostic testing for CML in the public setting in Kenya is limited and not covered by the Kenyan National Health Insurance Fund.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To establish a clinical fluorescence in situ hybridization assay for the diagnosis of CML in the Academic Model Providing Access to Healthcare (AMPATH) Reference Laboratory in Eldoret, Kenya.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>Peripheral blood and bone marrow smears were split between the AMPATH Reference Laboratory and the Indiana University Cytogenetics Laboratory for concordance studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>Seventeen specimens from patients with a provisional diagnosis of CML were studied by fluorescence in situ hybridization in both the AMPATH and Indiana University Cytogenetics laboratories. The analysis for 1 specimen could not be completed by both laboratories, and the results for 1 other specimen were discordant. The interpretations of 15 of 16 specimens (93.7%) were concordant. Normal specimens were also studied to establish the normal range for the assay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>We report the establishment of diagnostic testing for CML in the AMPATH Reference Laboratory and the Moi Teaching and Referral Hospital in Eldoret, Kenya.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2024-0264-oa","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T19:00:57Z","timestamp":1738177257000},"page":"613-617","source":"Crossref","is-referenced-by-count":0,"title":["Introducing Diagnostic Testing for Chronic Myeloid Leukemia in a Public Hospital Setting in Western Kenya"],"prefix":"10.5858","volume":"149","author":[{"given":"Millicent","family":"Orido","sequence":"first","affiliation":[{"name":"From the Academic Model Providing Access to Healthcare (AMPATH) Reference Laboratory, Eldoret, Kenya Indiana University School of Medicine, Indianapolis(Orido, Kigen)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa Cherop","family":"Lotodo","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, School of Medicine, Moi University, Eldoret, Kenya Indiana University School of Medicine, Indianapolis(Lotodo)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Kigen","sequence":"additional","affiliation":[{"name":"From the Academic Model Providing Access to Healthcare (AMPATH) Reference Laboratory, Eldoret, Kenya Indiana University School of Medicine, Indianapolis(Orido, Kigen)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Stohler","sequence":"additional","affiliation":[{"name":"From the Department of Medical and Molecular Genetics Indiana University School of Medicine, Indianapolis(Stohler, Vance)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry A.","family":"Vik","sequence":"additional","affiliation":[{"name":"From the Department of Medical and Pediatrics Indiana University School of Medicine, Indianapolis (Vik)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail H.","family":"Vance","sequence":"additional","affiliation":[{"name":"From the Department of Medical and Molecular Genetics Indiana University School of Medicine, Indianapolis(Stohler, Vance)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","reference":[{"key":"i1543-2165-149-7-613-b01","series-title":"WHO Classification of Tumours Editorial Board. Haematolymphoid Tumours","article-title":"Chronic myeloid leukaemia","volume":"11","author":"Apperley","year":"2024","unstructured":"Apperley\n              JF\n            ,\nGodleyLA,\nRadichJ, et al.\n          Chronic myeloid leukaemia. In: WHO Classification of Tumours Editorial Board. Haematolymphoid Tumours. 5th ed. Lyon, France: International Agency for Research on Cancer; 2024. WHO Classification of Tumours; vol 11. https:\/\/tumourclassification.iarc.who.int\/chapters\/63. Accessed June 16, 2024."},{"key":"i1543-2165-149-7-613-b02","series-title":"]. Science","first-page":"1497","article-title":"A minute chromosome in chronic granulocytic leukemia [abstract","volume":"132","author":"Nowell","year":"1960","unstructured":"Nowell\n              P\n            ,\nHungerfordD.\n          A minute chromosome in chronic granulocytic leukemia [abstract. ]. Science. 1960;132:1497."},{"issue":"5405","key":"i1543-2165-149-7-613-b03","series-title":"]. Nature","first-page":"290","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining [letter","volume":"243","author":"Rowley","year":"1973","unstructured":"Rowley\n              JD.\n            \n          \n          A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining [letter. ]. Nature. 1973;243(5405):290\u2013293. doi:10.1038\/243290a0"},{"issue":"5940","key":"i1543-2165-149-7-613-b04","series-title":"Nature","first-page":"239","article-title":"Localization of the c-abl oncogene to a translocation breakpoint in chronic myelocytic leukaemia","volume":"306","author":"Heisterkamp","year":"1983","unstructured":"Heisterkamp\n              N\n            ,\nStephensonJR,\nGroffenJ, et al.\n          Localization of the c-abl oncogene to a translocation breakpoint in chronic myelocytic leukaemia. Nature. 1983;306(5940):239\u2013242. doi:10.1038\/306239a0"},{"issue":"6020","key":"i1543-2165-149-7-613-b05","series-title":"Nature","first-page":"550","article-title":"Fused transcript of abl and bcr genes in chronic myelogenous leukaemia","volume":"315","author":"Shtivelman","year":"1985","unstructured":"Shtivelman\n              E\n            ,\nLifshitzB,\nGaleRP,\nCanaaniE.\n          Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985;315(6020):550\u2013554. doi:10.1038\/315550a0"},{"issue":"3","key":"i1543-2165-149-7-613-b06","series-title":"N Engl J Med","first-page":"164","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","unstructured":"Faderl\n              S\n            ,\nTalpazM,\nEstrovZ,\nO\u2019BrienS,\nKurzrockR,\nKantarjianHM.\n          The biology of chronic myeloid leukemia. N Engl J Med. 1999;341(3):164\u2013172. doi:10.1056\/NEJM199907153410306"},{"key":"i1543-2165-149-7-613-b07","series-title":"Methods Mol Biol","first-page":"311","article-title":"Interphase FISH studies of chronic myeloid leukemia","volume":"204","author":"Dewald","year":"2002","unstructured":"Dewald\n              GW.\n            \n          \n          Interphase FISH studies of chronic myeloid leukemia. Methods Mol Biol. 2002;204:311\u2013342. doi:10.1385\/1-59259-300-3:331"},{"issue":"9","key":"i1543-2165-149-7-613-b08","series-title":"Blood","first-page":"3357","article-title":"Highly sensitive fluorescence in situ hybridization method to detect double BCR\/ABL fusion and monitor response to therapy to chronic myeloid leukemia","volume":"91","author":"Dewald","year":"1998","unstructured":"Dewald\n              GW\n            ,\nWyattWA,\nJuneauAL, et al.\n          Highly sensitive fluorescence in situ hybridization method to detect double BCR\/ABL fusion and monitor response to therapy to chronic myeloid leukemia. Blood. 1998;91(9):3357\u20133365. doi:10.1182\/blood.V91.3357"},{"issue":"1","key":"i1543-2165-149-7-613-b09","series-title":"J Natl Compr Canc Netw","first-page":"43","article-title":"Chronic myeloid leukemia, version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Shah","year":"2024","unstructured":"Shah\n              N\n            ,\nBhatiaR,\nAltmanJK, et al.\n          Chronic myeloid leukemia, version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22(1):43\u201369. doi:10.6004\/jnccn.2024.0007"},{"key":"i1543-2165-149-7-613-b10","series-title":"Blood","first-page":"4541","article-title":"The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"118","author":"Jabbour","year":"2011","unstructured":"Jabbour\n              E\n            ,\nKantarjianH,\nO\u2019BrienS, et al.\n          The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood. 2011;118:4541\u20134546. doi:10.1182\/blood-2011-04-349110"},{"key":"i1543-2165-149-7-613-b11","series-title":"Blood","first-page":"1821","article-title":"How I treat childhood CML","volume":"19","author":"Andolina","year":"2012","unstructured":"Andolina\n              JR\n            ,\nNeudorfSM,\nCoreySJ.\n          How I treat childhood CML. Blood. 2012;19:1821\u20131830. doi:10.1182\/blood-2011-10-380774."},{"issue":"5","key":"i1543-2165-149-7-613-b12","series-title":"Nat Med","first-page":"561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","unstructured":"Druker\n              BJ\n            ,\nTamuraS,\nBuchdungerE, et al.\n          Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2(5):561\u2013566. doi:10.1038\/nm0596-561"},{"issue":"11","key":"i1543-2165-149-7-613-b13","series-title":"N Engl J Med","first-page":"994","article-title":"Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","unstructured":"O\u2019Brien\n              SG\n            ,\nGuilhotF,\nLarsonRA, et al.\n          Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994\u20131004. doi:10.1056\/NEJMoa022457"},{"issue":"1","key":"i1543-2165-149-7-613-b14","series-title":"J Hematol Oncol","first-page":"84","article-title":"Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy","volume":"11","author":"Rossari","year":"2018","unstructured":"Rossari\n              F\n            ,\nMinutoloF,\nOrciuoloE.\n          Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy. J Hematol Oncol. 2018;11(1):84. doi: 10.1186\/s13045\u2013018-0624-2"},{"issue":"6","key":"i1543-2165-149-7-613-b15","series-title":"CA Cancer J Clin","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","unstructured":"Bray\n              F\n            ,\nFerlayJ,\nSoejomataramI,\nSiegalRL,\nTorreLA,\nJemalA.\n          Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. doi:10.3322\/caac.21492"},{"key":"i1543-2165-149-7-613-b16","series-title":"Acad Med","first-page":"812","article-title":"Responding to the HIV pandemic: the power of an academic medical partnership","volume":"82","author":"Einterz","year":"2007","unstructured":"Einterz\n              RM\n            ,\nKimaiyoS,\nMengechHN, et al.\n          Responding to the HIV pandemic: the power of an academic medical partnership. Acad Med. 2007;82:812\u2013818. doi:10.1097\/ACM.0b013e3180cc29f1"},{"issue":"2","key":"i1543-2165-149-7-613-b17","series-title":"Infect Dis Clin North Am","first-page":"453","article-title":"Partnerships in international health. the Indiana University\u2013Moi University experience","volume":"9","author":"Einterz","year":"1995","unstructured":"Einterz\n              RM\n            ,\nKelleyCR,\nMamlinJJ, et al.\n          Partnerships in international health. the Indiana University\u2013Moi University experience. Infect Dis Clin North Am. 1995;9(2):453\u2013455."},{"issue":"1","key":"i1543-2165-149-7-613-b18","series-title":"Global Health","first-page":"44","article-title":"Leveraging the power of partnerships: spreading the vision for a population health care delivery model in western Kenya","volume":"14","author":"Mercer","year":"2018","unstructured":"Mercer\n              T\n            ,\nGardnerA,\nAndamaB, et al.\n          Leveraging the power of partnerships: spreading the vision for a population health care delivery model in western Kenya. Global Health. 2018;14(1):44. doi:10.1186\/s12992-018-0366-5"},{"issue":"3","key":"i1543-2165-149-7-613-b19","series-title":"East Afr Med J","first-page":"4604","article-title":"Geographical distribution of hematological malignancies managed at Moi Teaching and Referral hospital","volume":"99","author":"Lotodo","year":"2022","unstructured":"Lotodo\n              T\n            ,\nBurzibaN,\nChsumbaiG, et al.\n          Geographical distribution of hematological malignancies managed at Moi Teaching and Referral hospital. East Afr Med J. 2022;99(3):4604\u20134616."},{"key":"i1543-2165-149-7-613-b20","series-title":"Ecancermedicalscience","first-page":"1505","article-title":"Improvement in diagnosis in children with Burkitt lymphoma in Kenya: Implementation of fluorescence in situ hybridization testing for MYC and the MYC\/IGH translocation","volume":"17","author":"Vance","year":"2023","unstructured":"Vance\n              GH\n            ,\nLotodoT,\nKigenN, et al.\n          Improvement in diagnosis in children with Burkitt lymphoma in Kenya: Implementation of fluorescence in situ hybridization testing for MYC and the MYC\/IGH translocation. Ecancermedicalscience. 2023;17:1505. doi:10.3332\/ecancer.2023.1505"},{"issue":"1","key":"i1543-2165-149-7-613-b21","series-title":"Genet Med","first-page":"16","article-title":"Preclinical validation of fluorescence in situ hybridization assays for clinical practice","volume":"8","author":"Wiktor","year":"2006","unstructured":"Wiktor\n              AE\n            ,\nVan DykeDL,\nStupcaPJ, et al.\n          Preclinical validation of fluorescence in situ hybridization assays for clinical practice. Genet Med. 2006;8(1):16\u201323. doi:10.1097\/01.gim.0000195645.00446.61"},{"key":"i1543-2165-149-7-613-b22","author":"Standard: Establishment and verification of performance specifications. 42 CFR \u00a7493","unstructured":"Standard: Establishment and verification of performance specifications. 42 CFR \u00a7493\n          . 1253. https:\/\/www.govregs.com\/regulations\/title42_chapterIV-i3_part493_subpartK_subjgrp40_section493.1253. Accessed June 23, 2024."},{"issue":"4","key":"i1543-2165-149-7-613-b23","series-title":"Semin Hematol","first-page":"320","article-title":"Fluorescence in situ hybridization: uses and limitations","volume":"37","author":"Gozetti","year":"2000","unstructured":"Gozetti\n              A\n            ,\nLe BeauMM.\n          Fluorescence in situ hybridization: uses and limitations. Semin Hematol. 2000;37(4):320\u2013333. doi:10.1016\/s0037-1963(00)90013-1"},{"issue":"4","key":"i1543-2165-149-7-613-b24","series-title":"Clin Lab Med","first-page":"573","article-title":"Utility of fluorescence in situ hybridization in clinical and research applications","volume":"42","author":"Vance","year":"2022","unstructured":"Vance\n              GH\n            ,\nKhanWA.\n          Utility of fluorescence in situ hybridization in clinical and research applications. Clin Lab Med. 2022;42(4):573\u2013586. doi:10.1016\/j.cll.2022.09.020"},{"key":"i1543-2165-149-7-613-b25","author":"Moi Teaching and Referral Hospital","unstructured":"Moi Teaching and Referral Hospital\n          . https:\/\/www.mtrh.go.ke\/. Accessed September 30, 2024."}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"link":[{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/149\/7\/article-p613.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/meridian.allenpress.com\/aplm\/article-pdf\/149\/7\/613\/3527645\/i1543-2165-149-7-613.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/149\/7\/article-p613.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/149\/7\/article-p613.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T01:55:55Z","timestamp":1784166955000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/149\/7\/article-p613.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":25,"journal-issue":{"issue":"7"},"URL":"https:\/\/doi.org\/10.5858\/arpa.2024-0264-oa","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}